CXCL12 secreted by pancreatic stellate cells accelerates gemcitabine resistance of pancreatic cancer by enhancing glycolytic reprogramming

References

• Amrutkar M, Aasrum M, Verbeke CS, Gladhaug IP. 2019. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. BMC Cancer. 19:596.
   PubMed Web of Science ®Google Scholar
• Braun M, Qorraj M, Buttner M, Klein FA, Saul D, Aigner M, Huber W, Mackensen A, Jitschin R, Mougiakakos D. 2016. CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis. Leukemia. 30:1788–1792.
   PubMed Web of Science ®Google Scholar
• Cui J, Guo Y, Wu H, Xiong J, Peng T. 2021. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling. Mol Med. 27:38.
   PubMed Web of Science ®Google Scholar
• Dai S, Peng Y, Zhu Y, Xu D, Zhu F, Xu W, Chen Q, Zhu X, Liu T, Hou C, et al. 2020. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. Biomed Pharmacother. 121:109521.
   PubMed Web of Science ®Google Scholar
• Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, et al. 2013. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 110:20212–20217.
   PubMed Web of Science ®Google Scholar
• Feng M, Xiong G, Cao Z, Yang G, Zheng S, Qiu J, You L, Zheng L, Zhang T, Zhao Y. 2018. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. J Exp Clin Cancer Res. 37:274.
   PubMed Web of Science ®Google Scholar
• Garg B, Giri B, Modi S, Sethi V, Castro I, Umland O, Ban Y, Lavania S, Dawra R, Banerjee S, et al. 2018. NFkappab in pancreatic stellate cells reduces infiltration of tumors by cytotoxic T cells and killing of cancer cells, via Up-regulation of CXCL12. Gastroenterology. 155:880–891.e888.
   PubMed Web of Science ®Google Scholar
• Hu LP, Zhang XX, Jiang SH, Tao LY, Li Q, Zhu LL, Yang MW, Huo YM, Jiang YS, Tian GA, et al. 2019. Targeting purinergic receptor P2Y2 prevents the growth of pancreatic ductal adenocarcinoma by inhibiting cancer cell glycolysis. Clin Cancer Res. 25:1318–1330.
   PubMed Web of Science ®Google Scholar
• Huang WK, Chen Y, Su H, Chen TY, Gao J, Liu Y, Yeh CN, Li S. 2021. ARHGAP25 inhibits pancreatic adenocarcinoma growth by suppressing glycolysis via AKT/mTOR pathway. Int J Biol Sci. 17:1808–1820.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, Takaori K. 2016. Pancreatic cancer. Lancet. 388:73–85.
   PubMed Web of Science ®Google Scholar
• Latenstein AEJ, van der Geest LGM, Bonsing BA, Groot Koerkamp B, Haj Mohammad N, de Hingh I, de Meijer VE, Molenaar IQ, van Santvoort HC, van Tienhoven G, et al. 2020. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer. 125:83–93.
   PubMed Web of Science ®Google Scholar
• Li R, Weng L, Liu B, Zhu L, Zhang X, Tian G, Hu L, Li Q, Jiang S, Shang M. 2020. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis. J Cell Biochem. 121:1986–1997.
   PubMed Web of Science ®Google Scholar
• Liao YX, Lv JY, Zhou ZF, Xu TY, Yang D, Gao QM, Fan L, Li GD, Yu HY, Liu KY. 2021. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3KAktmTOR pathway inhibition. Int J Oncol. 59:49.
   Web of Science ®Google Scholar
• Liu S, Hu C, Li M, An J, Zhou W, Guo J, Xiao Y. 2022. Estrogen receptor beta promotes lung cancer invasion via increasing CXCR4 expression. Cell Death Dis. 13:70.
   PubMed Web of Science ®Google Scholar
• Liu SL, Cao SG, Li Y, Sun B, Chen D, Wang DS, Zhou YB. 2019. Pancreatic stellate cells facilitate pancreatic cancer cell viability and invasion. Oncol Lett. 17:2057–2062.
   PubMed Web of Science ®Google Scholar
• Morimoto M, Matsuo Y, Koide S, Tsuboi K, Shamoto T, Sato T, Saito K, Takahashi H, Takeyama H. 2016. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. BMC Cancer. 16:305.
   PubMed Web of Science ®Google Scholar
• Moutinho-Ribeiro P, Macedo G, Melo SA. 2018. Pancreatic cancer diagnosis and management: has the time come to prick the bubble? Front Endocrinol (Lausanne). 9:779.
   PubMed Web of Science ®Google Scholar
• Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. 2016. Key role of pancreatic stellate cells in pancreatic cancer. Cancer Lett. 381:194–200.
   PubMed Web of Science ®Google Scholar
• Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, et al. 2011. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 71:5522–5534.
   PubMed Web of Science ®Google Scholar
• Sarvepalli D, Rashid MU, Rahman AU, Ullah W, Hussain I, Hasan B, Jehanzeb S, Khan AK, Jain AG, Khetpal N, et al. 2019. Gemcitabine: a review of chemoresistance in pancreatic cancer. Crit Rev Oncog. 24:199–212.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. 2022. Cancer statistics, 2022. CA Cancer J Clin. 72:7–33.
   PubMed Web of Science ®Google Scholar
• Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP. 2010. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer. 103:1671–1679.
   PubMed Web of Science ®Google Scholar
• Sleightholm RL, Neilsen BK, Li J, Steele MM, Singh RK, Hollingsworth MA, Oupicky D. 2017. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. Pharmacol Ther. 179:158–170.
   PubMed Web of Science ®Google Scholar
• Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H, et al. 2016. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 536:479–483.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. 2010. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
   PubMed Web of Science ®Google Scholar
• Wei L, Ye H, Li G, Lu Y, Zhou Q, Zheng S, Lin Q, Liu Y, Li Z, Chen R. 2018. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Cell Death Dis. 9:1065.
   PubMed Web of Science ®Google Scholar
• Xi Y, Yuan P, Li T, Zhang M, Liu MF, Li B. 2020. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer. Cancer Lett. 479:112–122.
   PubMed Web of Science ®Google Scholar
• Xu F, Huang M, Chen Q, Niu Y, Hu Y, Hu P, Chen D, He C, Huang K, Zeng Z, et al. 2021. LncRNA HIF1A-AS1 promotes gemcitabine resistance of pancreatic cancer by enhancing glycolysis through modulating the AKT/YB1/HIF1alpha pathway. Cancer Res. 81:5678–5691.
   PubMed Web of Science ®Google Scholar
• Yan L, Tu B, Yao J, Gong J, Carugo A, Bristow CA, Wang Q, Zhu C, Dai B, Kang Y, et al. 2021. Targeting glucose metabolism sensitizes pancreatic cancer to MEK inhibition. Cancer Res. 81:4054–4065.
   PubMed Web of Science ®Google Scholar
• Yang F, Takagaki Y, Yoshitomi Y, Ikeda T, Li J, Kitada M, Kumagai A, Kawakita E, Shi S, Kanasaki K, et al. 2019. Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis. Cancer Res. 79:735–746.
   PubMed Web of Science ®Google Scholar
• Yi J, Gao ZF. 2019. MicroRNA-9-5p promotes angiogenesis but inhibits apoptosis and inflammation of high glucose-induced injury in human umbilical vascular endothelial cells by targeting CXCR4. Int J Biol Macromol. 130:1–9.
   PubMed Web of Science ®Google Scholar
• Yi L, Zhou X, Li T, Liu P, Hai L, Tong L, Ma H, Tao Z, Xie Y, Zhang C, et al. 2019. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4. J Exp Clin Cancer Res. 38:339.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lou Y, Zhang J, Fu Q, Wei T, Sun X, Chen Q, Yang J, Bai X, Liang T. 2017. Hypoxia-inducible factor-2alpha promotes tumor progression and has crosstalk with Wnt/beta-catenin signaling in pancreatic cancer. Mol Cancer. 16:119.
   PubMed Web of Science ®Google Scholar
• Zhao W, Ajani JA, Sushovan G, Ochi N, Hwang R, Hafley M, Johnson RL, Bresalier RS, Logsdon CD, Zhang Z, et al. 2018. Galectin-3 mediates tumor cell-stroma interactions by activating pancreatic stellate cells to produce cytokines via integrin signaling. Gastroenterology. 154:1524–1537.e1526.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wu C, Yang J, Zhao Y, Jia H, Xue M, Xu D, Yang F, Fu D, Wang C, et al. 2020. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Signal Transduct Target Ther. 5:53.
   PubMed Web of Science ®Google Scholar